Speaker Profile
PhD, Director of Gene Editing Specificity, Mammoth Bio
Biography
Maggie's current work focuses on characterizing the safety and in vivo characteristics of genome modifying enzymes for therapeutically relevant targets. She has also developed synthetic biology programs for CART cells using CRISPRi and CRISPRa. Maggie was a postdoctoral fellow at MGH and completed her graduate school studies at City of Hope.
Emerging Therapeutics Showcase:
Mammoth Bio
Mammoth Biosciences has built a broad portfolio of CRISPR technologies leveraging its protein discovery and engineering platform. The company is focused on developing its proprietary ultracompact CRISPR systems for in vivo gene editing in difficult to reach tissues to enable curative therapies.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
